EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Mesothelin promotes acute myeloid leukemia progression through LYN-dependent signaling

Joshua R Faust, Darcy Hamill, E Anders Kolb, Alexandra M Stevens, Anilkumar Gopalakrishnapillai, Sonali P Barwe

Journal of Biological Chemistry · 2026

DOI: 10.1016/j.jbc.2026.111390 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2026. Verfasst von Joshua R Faust und 5 weiteren Autor:innen. Beteiligte Einrichtung: Lisa Dean Moseley Foundation Institute for Cancer and Blood Disorders, Nemours Children's Hospital, Delaware, Wilmington, Delaware, USA; Department o…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, src-Family Kinases, Signal Transduction, GPI-Linked Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Cancer Institute, Kansas IDeA Network of Biomedical Research Excellence, US Department of Defense.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mesothelin (MSLN) is a glycosylphosphatidylinositol-anchored cell surface protein that is overexpressed in several solid tumors and in one-third of pediatric acute myeloid leukemia (AML) cases. It represents a validated immunotherapeutic target owing to its lack of expression in normal bone marrow. The function of MSLN in AML is unknown, but it is implicated to regulate adhesion in solid tumors through interaction with its only known binding partner, MUC16/CA125. This study uses CRISPR/Cas9 mutagenesis to generate knockout (KO) of MSLN in NOMO-1 and a MSLN-expressing patient-derived xenograft model to investigate its biological role in AML. We show that MSLN-KO cells proliferate slower, have reduced mitochondrial metabolism, are arrested in G1 cell cycle phase, adhere less to extracellular matrix in vitro and engraft slower in vivo. MSLN-KO cells also exhibit increased sensitivity to Ara-C and reduced extracellular matrix-mediated chemoprotection. Using an unbiased approach, we identify Src-family kinase member LYN, and guanine nucleotide-binding protein G(i) alpha subunit proteins, GNAI1, GNAI2, and GNAI3 as novel binding partners of MSLN in AML and show that pharmacological or genetic inhibition of LYN signaling restores NOMO-1 cell sensitivity to Ara-C. Together, these findings demonstrate that MSLN functions as an oncogenic driver in AML and reveal a previously unrecognized MSLN-LYN signaling axis, the therapeutic targeting of which may enhance responses to chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, Acutesrc-Family KinasesSignal TransductionGPI-Linked ProteinsMesothelinHumansAnimalsMiceDisease ProgressionCell Proliferation

Stichwörter der Autor:innen

GPI-anchored proteinLYNacute myeloid leukemiaadhesioncell proliferationchemoresistancemesothelin

Substanzen

Mesothelinlyn protein-tyrosine kinasesrc-Family KinasesGPI-Linked ProteinsMSLN protein, human

Autor:innen und Institutionen

  • Lisa Dean Moseley Foundation Institute for Cancer and Blood Disorders, Nemours Children's Hospital, Delaware, Wilmington, Delaware, USA; Department of Biological Sciences, University of Delaware, Newark, Delaware, USA.
  • Lisa Dean Moseley Foundation Institute for Cancer and Blood Disorders, Nemours Children's Hospital, Delaware, Wilmington, Delaware, USA.
  • Section of Hematology/Oncology, Department of Pediatrics, Texas Children's Cancer and Hematology Center, Baylor College of Medicine, Houston, Texas, USA.
  • Lisa Dean Moseley Foundation Institute for Cancer and Blood Disorders, Nemours Children's Hospital, Delaware, Wilmington, Delaware, USA; Department of Biological Sciences, University of Delaware, Newark, Delaware, USA.…

Förderung

  • National Cancer Institute
  • Kansas IDeA Network of Biomedical Research Excellence
  • US Department of Defense
  • Cancer Prevention and Research Institute of Texas
  • Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine
  • Leukemia and Lymphoma Society
  • National Institute of General Medical Sciences
  • Texas Children's Hospital

Zitieren

APA

Faust, J. R., Hamill, D., Kolb, E. A., Stevens, A. M., Gopalakrishnapillai, A., & Barwe, S. P. (2026). Mesothelin promotes acute myeloid leukemia progression through LYN-dependent signaling. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2026.111390

Vancouver

Faust JR, Hamill D, Kolb EA, Stevens AM, Gopalakrishnapillai A, Barwe SP. Mesothelin promotes acute myeloid leukemia progression through LYN-dependent signaling. Journal of Biological Chemistry. 2026. doi:10.1016/j.jbc.2026.111390

BibTeX
@article{Faust2026,
  author = {Faust, Joshua R and Hamill, Darcy and Kolb, E Anders and Stevens, Alexandra M and Gopalakrishnapillai, Anilkumar and Barwe, Sonali P},
  title = {Mesothelin promotes acute myeloid leukemia progression through LYN-dependent signaling},
  journal = {Journal of Biological Chemistry},
  year = {2026},
  doi = {10.1016/j.jbc.2026.111390}
}
Kostenlos starten →